http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
폐결핵환자의 치료 시점에 따른 말초혈액 단핵구의 IFN-$\gamma$, TNF-$\alpha$ 분비능의 변화
임재준,이상민,이재호,유철규,이춘택,정희순,김영환,한성구,심영수,Yim, Jae-Joon,Lee, Sang-Min,Lee, Jae-Ho,Yoo, Chul-Gyu,Lee, Choon-Taek,Chung, Hee-Soon,Kim, Young-Whan,Han, Sung-Koo,Shim, Young-Soo 대한결핵및호흡기학회 2000 Tuberculosis and Respiratory Diseases Vol.48 No.2
배 경: 결핵에 대한 인체의 면역반응의 근간을 이루는 것은 대식세포가 결핵균을 탐식하여 사멸시키는 것이다. 이 과정에는 Interferon-gamma(IFN-$\gamma$)와 Tumor necrosis factor-alpha(TNF-$\alpha$) 가 중요한 역할을 한다. 저자들은 phytohemagglutinin(PHA) 혹은 purified protein derivative(PPD)에 의한 말초혈액 단핵구의 IFN-$\gamma$와 TNF-$\alpha$의 분비능이 폐결핵 환자들에서 치료함에 따라 어떻게 변화하는지를 살펴보고자하였다. 방 법: 폐결핵으로 확진되었고 전형적인 임상상을 보이는 치료시작 전 환자 5명, 치료시작 후 4개월이내의 환자 11명, 치료시작 후 4 개월에서 9개월 사이의 환자 6명 그리고 치료를 종료한 환자 7명을 대상으로 하였다. 환자의 말초혈액 단핵구를 분리하여 PHA와 PPD로 자극한 후 IFN-$\gamma$와 TNF-$\alpha$를 측정하여 서로 비교하였다. 결 과: 각 군간에 PHA와 PPD로 자극한 후 말초혈액 단핵구의 IFN-$\gamma$와 TNF-$\alpha$의 분비능은 차이가 없었다. 결 론: 전형적인 임상상을 보이는 폐결핵환자들에서 그 치료 시점에 따른 IFN-$\gamma$와 TNF-$\alpha$의 분비능의 차이는 없었다. Background: Interleron-gamma(IFN-$\gamma$) and tumor necrosis factor-alpha(TNF-$\alpha$) playa critical role in protective immunity against Mycobacterium tuberculosis infection The change of IFN-$\gamma$ and TNF -$\alpha$ producing capacity in the course of antituberculous chemotherapy in patients with pulmonary tuberculosis was evaluated in this study. Method: In 29 patients with pulmonary tuberculosis, phytohemagglutinin(PHA) or purified protein derivative(PPD) stimulated production of IFN-$\gamma$ and TNF-$\alpha$ by peripheral blood mononuclear cells was quantified. Five patients were sampled before they underwent antituberculous treatment, 11 patients after 0-4 months, six after 4-completion and seven after treatment completion. Result: There was no difference in PHA- or PPD-stimulated production of IFN-$\gamma$ and TNF-$\alpha$ between each group. Conclusion: No difference in PHA- or PPD- stimulated production of IFN-$\gamma$ and TNF-$\alpha$ between two groups could be identified according to their treatment with pulmonary tuberculosis.
임재준 ( Jae Joon Yim ) 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.71 No.6
Tuberculosis is one of the leading causes of mortality and morbidity worldwide. In 2010, there were 8.8 million (range, 8.5∼9.2 million) incident cases of TB, 1.1 million deaths from TB among HIV-negative people and an additional 0.35 million deaths from HIV-associated TB. Due to such health-related importance, tuberculosis is one of areas being actively researched. Many numbers of tuberculosis-related papers are being presented each year, and in this review, it summarizes contents of a few papers that had been selected among the papers presented from 2009 to early 2011.
임재준 ( Jae Joon Yim ) 대한내과학회 2011 대한내과학회지 Vol.81 No.2
Tuberculous (TB) pleuritis is the second most common form of extrapulmonary tuberculosis. Because the yield of pleural fluid mycobacterial culture is as low as 20% and the pleural biopsy is rather invasive, the measurement of adenosine deaminase (ADA) has been a cornerstone of the diagnosis of TB pleuritis. If the ADA level of pleural fluid is higher than 70 IU/L, the diagnosis of TB pleuritis can be made safely. The treatment is based on a standard short course anti-TB treatment starting with isoniazid, rifampicin, ethambutol, and pyrazinamide. Although systemic steroids and drainage of pleural fluid have been tried to reduce the residualpleural thickening, the results are contradicting. (Korean J Med 2011;81:150-153)
신종 감염병의 최신 지견 ; 내성 결핵균의 실태 및 치료
임재준 ( Jae Joon Yim ) 대한내과학회 2009 대한내과학회지 Vol.77 No.2
Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients. (Korean J Med 77:152-156, 2009)
전신성 홍반성 낭창 환자에서 발생한 Mycobacterium abscessus에 의한 폐렴
임재준 ( Jae Joon Yim ),오명돈 ( Myoung Don Oh ),유철규 ( Chul Gyu Yoo ),송영욱 ( Yeong Wook Song ),김영환 ( Young Whan Kim ),서정욱 ( Jung Wook Seo ),한성구 ( Sung Gu Han ),최강원 ( Kang Won Choe ),심영수 ( Young Soo Shim ) 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.46 No.1
폐결핵환자의 치료 시점에 따른 말초혈액 단핵구의 IFN-γ, TNF-α 분비능의 변화
임재준 ( Jae Joon Yim ),이상민 ( Sang Min Lee ),이재호 ( Jae Ho Lee ),유철규 ( Chul Gyu Yoo ),이춘택 ( Choon Taek Lee ),정희순 ( Hee Soon Chung ),김영환 ( Young Whan Kim ),한성구 ( Sung Koo Han ),심영수 ( Young Soo Shim ) 대한결핵 및 호흡기학회 2000 Tuberculosis and Respiratory Diseases Vol.48 No.2